Efficas

About Efficas

Efficas Inc., established in 2003, operates as a health-science and technology firm focused on the nutritional management of the immune system for both humans and animals. The company directs its efforts towards researching, developing, and commercializing products that provide relief from allergic conditions and asthma. Headquartered in Fullerton, California, the privately-held company has raised $32 million in funding, with investors including Luberski Holdings.

The company's product development is rooted in extensive scientific research, including clinical trials and safety testing. A key figure behind the company's formulation is Dr. Floyd H. “Ski” Chilton, a research scientist recognized for his work on fatty acids in human inflammatory diseases. After seven years of research, Dr. Chilton and his colleagues discovered that a specific combination and ratio of two essential fatty acids, Gamma-Linolenic acid (GLA) from borage oil and Eicosapentaenoic acid (EPA) from fish oil, could significantly reduce the production of leukotrienes. Leukotrienes are inflammatory molecules that cause symptoms associated with asthma and allergies, such as airway narrowing, mucus production, and tissue swelling.

Efficas markets this patented formula as a non-prescription medical food called Efficas Care. This product is designed to inhibit the body's production of leukotrienes, offering a natural approach to managing symptoms like sinus congestion, coughing, and shortness of breath. The product is delivered in an emulsified form, which studies have shown increases the bioavailability of GLA and EPA compared to traditional oil capsules. Clinical trial results indicated that over 70% of asthma sufferers reported a significant improvement in their quality of life after using the product. Efficas primarily sells directly to consumers who are proactively seeking safe and proven nutritional products to manage their health conditions.